-

Bristol Myers Squibb Reports Third Quarter Financial Results for 2025

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today reported third quarter 2025 financial results.

Visit the company’s Investor Relations website at http://investor.bms.com to view the detailed third quarter 2025 earnings press release and investor presentation.

The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, October 30, 2025, which is accessible here. Company executives will review financial results with the investment community during the call.

A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes.

About Bristol Myers Squibb: Transforming Patients' Lives Through Science
At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com and follow us on LinkedIn, X, YouTube, Facebook and Instagram.

corporatefinancial-news

Contacts

For more information, contact:
Media Relations: media@bms.com
Investor Relations: investor.relations@bms.com

Bristol Myers Squibb

NYSE:BMY

Release Summary
Bristol Myers Squibb Reports Third Quarter Financial Results for 2025
Release Versions

Contacts

For more information, contact:
Media Relations: media@bms.com
Investor Relations: investor.relations@bms.com

More News From Bristol Myers Squibb

U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma

PRINCETON, N.J.--(BUSINESS WIRE)--US FDA Grants Priority Review to Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Chemotherapy Combination for Classic Hodgkin Lymphoma...

Bristol Myers Squibb Announces Dividend Increase

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend Increase...

Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025...
Back to Newsroom